📊 FOLD Key Takeaways
Is FOLD a Good Investment? Thesis Analysis
Amicus demonstrates strong revenue growth (+20% YoY) and solid operational cash generation ($33.1M), with excellent gross margins (88.5%) typical of pharmaceutical companies. However, the company remains unprofitable at the net level (-4.3% margin) despite positive operating income, and carries significant debt ($392.7M) relative to equity, requiring careful monitoring of cash burn and profitability trajectory.
Why Buy FOLD? Key Strengths
- Strong revenue growth of 20% YoY indicating market traction and potential product expansion
- Excellent gross margin of 88.5% demonstrating pricing power and operational efficiency
- Positive operating cash flow ($33.1M) and free cash flow ($29.8M) providing financial flexibility
- Healthy liquidity position with current ratio of 2.84x and $214M cash on hand
- Operating profitability ($32.8M) suggests core business viability
FOLD Investment Risks to Consider
- Negative net income (-$27.1M) despite positive operations indicates significant non-operating expenses or tax impacts masking underlying profitability
- High leverage with debt-to-equity ratio of 1.43x and long-term debt of $392.7M relative to $274.2M equity creates financial risk
- Marginal interest coverage ratio of 2.6x leaves limited buffer for operational deterioration or interest rate increases
- Negative ROE (-9.9%) and ROA (-2.9%) indicate capital inefficiency and shareholder value destruction
- Low operating margin (5.2%) relative to industry standards suggests competitive pressures or high operating costs
Key Metrics to Watch
- Path to sustained net profitability and net margin expansion
- Debt reduction progress and trajectory toward more sustainable leverage ratios
- Revenue sustainability and whether 20% growth rate can be maintained
- Operating expense management and operating margin improvement
- Cash burn rate relative to free cash flow generation
FOLD Financial Metrics
💡 AI Analyst Insight
The relatively thin 4.7% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.84x current ratio provides a solid financial cushion.
FOLD Profitability Ratios
FOLD vs Healthcare Sector
How AMICUS THERAPEUTICS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FOLD Overvalued or Undervalued?
Based on fundamental analysis, AMICUS THERAPEUTICS, INC. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FOLD Balance Sheet & Liquidity
FOLD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: AMICUS THERAPEUTICS, INC.'s revenue has grown significantly by 108% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
FOLD Growth Metrics (YoY)
FOLD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $141.5M | -$6.7M | $-0.02 |
| Q2 2025 | $126.7M | -$15.7M | $-0.05 |
| Q1 2025 | $110.4M | -$21.7M | $-0.07 |
| Q3 2024 | $103.5M | -$6.7M | $-0.02 |
| Q2 2024 | $94.5M | -$15.7M | $-0.05 |
| Q1 2024 | $86.3M | -$48.4M | $-0.16 |
| Q3 2023 | $81.7M | -$21.6M | $-0.07 |
| Q2 2023 | $80.7M | -$43.2M | $-0.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
FOLD Capital Allocation
FOLD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for AMICUS THERAPEUTICS, INC. (CIK: 0001178879)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FOLD
What is the AI rating for FOLD?
AMICUS THERAPEUTICS, INC. (FOLD) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are FOLD's key strengths?
Claude: Strong revenue growth of 20% YoY indicating market traction and potential product expansion. Excellent gross margin of 88.5% demonstrating pricing power and operational efficiency.
What are the risks of investing in FOLD?
Claude: Negative net income (-$27.1M) despite positive operations indicates significant non-operating expenses or tax impacts masking underlying profitability. High leverage with debt-to-equity ratio of 1.43x and long-term debt of $392.7M relative to $274.2M equity creates financial risk.
What is FOLD's revenue and growth?
AMICUS THERAPEUTICS, INC. reported revenue of $634.2M.
Does FOLD pay dividends?
AMICUS THERAPEUTICS, INC. does not currently pay dividends.
Where can I find FOLD SEC filings?
Official SEC filings for AMICUS THERAPEUTICS, INC. (CIK: 0001178879) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FOLD's EPS?
AMICUS THERAPEUTICS, INC. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FOLD a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, AMICUS THERAPEUTICS, INC. has a HOLD rating with 62% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FOLD stock overvalued or undervalued?
Valuation metrics for FOLD: ROE of -9.9% (sector avg: 15%), net margin of -4.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FOLD stock in 2026?
Our dual AI analysis gives AMICUS THERAPEUTICS, INC. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FOLD's free cash flow?
AMICUS THERAPEUTICS, INC.'s operating cash flow is $33.1M, with capital expenditures of $3.3M. FCF margin is 4.7%.
How does FOLD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4.3% (avg: 12%), ROE -9.9% (avg: 15%), current ratio 2.84 (avg: 2).